Monitor for additional insider purchases in the coming weeks; if buying continues, it could signal stronger conviction. Next catalyst is the annual meeting and any updates on guidance. The EPS miss due to one-time costs may be temporary, but guidance maintained provides some reassurance.
Price Chart
Executive Summary
Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 earnings release. Revenue of $29.6M beat consensus but GAAP EPS of -$0.37 missed estimates. The insider buying suggests confidence in the company's outlook, but the EPS miss tempers enthusiasm.
Key Financial Metrics
Key Facts
- CEO Stephen Griffin purchased 12,200 shares for ~$150K at $12.29 on April 30.
- Director John Henneman III purchased 5,000 shares for ~$73K at $14.66 on May 1.
- Q1 2026 revenue $29.6M (+13% YoY) beat consensus of $28.1M.
- Q1 2026 GAAP EPS -$0.37 missed consensus -$0.21, with $4.9M in severance costs.
- Total insider buying $223K represents ~0.11% of market cap ($198M).
Financial Impact
$223K in insider purchases (0.11% of market cap)
Risk Factors
- Q1 EPS miss of 76% versus consensus may weigh on sentiment despite revenue beat.
- Two director resignations announced with earnings could signal governance issues.
- Modest insider buying relative to market cap limits signal strength.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ANIK-1777898119851 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access